Hemanext

Name

Hemanext

Legal name

Hemanext Inc.

Website

https://hemanext.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

51–100 employees

Short description

Hemanext is a medical technology company that develops and sells the FDA-authorized Hemanext ONE disposable blood processing and storage system, which preserves red blood cell quality under hypoxic conditions for supply to hospital transfusion services.

Ownership category

akta.pro rank

Product category

Blood Storage Medical Devices

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH)

akta.pro secondary industry

Single-Use Technologies (SUT) & Disposable Fluid Management (bags, assemblies, connectors) (HLAAAJAC)

Keywords

• Blood storage devices
• Red blood cell processing
• Transfusion medicine
• Hypoxic blood storage
• Medical device disposables

Headquarters

HQ city

Lexington

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Hemanext ONE Disposable Kit Sales: Hemanext sells disposable Hemanext ONE processing and storage kit sets to blood establishments (blood centers). Blood establishments use the kits to process and store hypoxic red blood cells, which are then supplied to hospitals for transfusion. The model is a pure consumables/disposables model with no upfront capital equipment required from customers. Revenue is generated per unit of disposable kit sold to blood establishments.
2. Hypoxic Red Blood Cell Supply: Blood establishments (such as OneBlood and Vitalant) that produce hypoxic RBCs using Hemanext ONE supply these units to hospitals. While revenue to Hemanext comes from disposable kit sales, the end-product (oxygen-controlled RBC) is billed by blood establishments to hospitals under CMS HCPCS code P9027 at approximately $487 per unit for outpatient use — nearly 3x the rate for conventional RBC.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Hemanext develops and manufactures the Hemanext ONE System, a first-in-class FDA-authorized and CE-marked disposable medical device that processes and stores red blood cells under oxygen-controlled (hypoxic) conditions. The system consists of an Oxygen Reduction Bag (ORB) that deoxygenates RBCs in approximately 3 to 3.5 hours and a Hemanext Storage Bag (HSB) that maintains hypoxic conditions throughout the 42-day refrigerated shelf life, preserving RBC metabolism, deformability, and post-transfusion recovery. The company sells disposable kits directly to blood establishments (blood centers) on a pure consumables basis with no capital equipment required.

Product overview

Hemanext offers a unified medical device product called Hemanext ONE, which is the first and only FDA-authorized and CE-marked blood storage system for oxygen-controlled storage of red blood cells. The system consists of two integrated components: the Oxygen Reduction Bag (ORB) that deoxygenates blood during processing, and the Hemanext Storage Bag (HSB) that maintains hypoxic conditions throughout storage. Together, these components preserve red blood cell quality, metabolism, and function for up to 42 days.

Differentiator

Problem solved

Functional benefit

Brands

• Hemanext ONE: First and only FDA-authorized and CE-marked blood storage system that processes and stores red blood cells under oxygen-controlled conditions. The system includes the Oxygen Reduction Bag (ORB) and Hemanext Storage Bag (HSB) components.

Products and services

• Hemanext ONE System A first-in-class FDA-authorized and CE-marked disposable medical device system for processing and storing red blood cells under oxygen-controlled (hypoxic) conditions. The system comprises an Oxygen Reduction Bag (ORB) that removes oxygen and carbon dioxide from RBCs in approximately 3 to 3.5 hours using an iron-based sorbent layer, plus a Hemanext Storage Bag (HSB) with double-wall design that prevents oxygen ingress during 42-day refrigerated storage. Sold to blood establishments (blood centers) on a per-unit consumables basis.

Quantifiable outcome

• In human kidney perfusion model, oxygen-controlled RBC demonstrated 68% increased oxygen diffusion capacity and 20% increased renal respiratory rate vs conventional RBC
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• OneBloodcoreStrategic or Co-development Partner · 6 July 2026Strategic production partnership with OneBlood, one of the nation's largest independent blood centers, marking a significant milestone in Hemanext's U.S. commercial expansion. OneBlood will begin production of hypoxic RBCs using Hemanext ONE at all three of its blood processing facilities located in Charlotte, North Carolina; St. Petersburg, Florida; and Orlando, Florida. OneBlood serves approximately 250+ hospitals across Florida, Georgia, and the Carolinas, supplying ~900,000 RBC units annually (~7% of U.S. national blood supply).
• Hemara BiocoreChannel Partner/ Reseller/ Distributor · 29 October 2024Exclusive distribution agreement with Hemara Bio (Dubai, UAE) covering the Gulf Cooperation Council (GCC) region — UAE, Qatar, Kuwait, and Saudi Arabia. The partnership addresses increasing need for safe and efficient blood transfusions in a region where hemoglobinopathies (sickle cell disease, thalassemia) are prevalent. Hemara Bio brings local market expertise and distribution infrastructure.
• Vitalant Innovation CenterminorStrategic or Co-development PartnerHemanext collaborates with Vitalant's Innovation Center to accelerate development and deployment of new blood safety solutions. This partnership supports research collaboration and product development in addition to Vitalant's investment.

Scale indicators6 records

Recent moves7 records

Expansion highlights8 records

Broad incumbents

• Fresenius Kabi: Fresenius Kabi manufactures blood collection sets, storage bags, and transfusion medical devices. Comparable to Hemanext as an established supplier of disposable blood storage and processing products to blood centers and hospitals.
• Terumo Blood and Cell Technologies: Terumo BCT (a Terumo subsidiary) is a major incumbent in blood component collection, processing, and storage equipment, including apheresis systems. Comparable to Hemanext as a broader blood banking and transfusion medicine technology player with overlapping hospital/customer base.
• Haemonetics: Haemonetics is a global medical device company focused on blood and plasma component collection, apheresis, and hospital software. Comparable to Hemanext given shared customer base of blood centers and hospitals and adjacent product portfolio in blood processing.
• Grifols: Grifols is a global blood products and transfusion diagnostics company, operating blood donor centers and producing plasma-derived therapies and blood typing reagents. Comparable to Hemanext through shared involvement in the blood banking and transfusion medicine supply chain.
• Immucor: Immucor is a transfusion diagnostics company that provides blood bank reagents and instruments (immunohematology). Hemanext board member Geoff Crouse is a former COO of Immucor. Comparable as a focused transfusion/blood bank supplier.
• Ortho Clinical Diagnostics: Ortho Clinical Diagnostics provides immunohematology and blood bank testing systems to hospitals and blood centers globally. Comparable to Hemanext as an established vendor in the blood bank/transfusion medicine space serving the same end customers.
• Bio-Rad Laboratories: Bio-Rad's Life Science and Clinical Diagnostics segments include blood bank quality controls and immunohematology reagents. Comparable as an incumbent supplier serving the blood banking customer base that Hemanext also targets.

Direct peers

• MacoPharma: MacoPharma is a leading European manufacturer of blood collection, processing, and storage bags for transfusion medicine. It is directly comparable to Hemanext as both companies supply disposable blood storage bag systems to blood centers and hospitals globally.
• Cerus Corporation: Cerus develops the INTERCEPT pathogen reduction system for platelets and plasma, used by blood centers globally. Comparable to Hemanext as a blood safety/quality-focused medical device company selling disposable systems to blood establishments with value-based reimbursement.

Emerging players

• Quotient Limited: Quotient develops transfusion diagnostics including the MosaiQ blood bank testing platform. Comparable to Hemanext as a focused transfusion medicine diagnostics/tools company serving blood centers and hospital transfusion services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds10 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hemanext